BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30194181)

  • 1. Radiological Features of IDO1
    Takada K; Toyokawa G; Tagawa T; Shimokawa M; Kohashi K; Haro A; Osoegawa A; Oda Y; Maehara Y
    Anticancer Res; 2018 Sep; 38(9):5295-5303. PubMed ID: 30194181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
    Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.
    Ishihara S; Yamada Y; Iwasaki T; Yoshimoto M; Toda Y; Kohashi K; Yamamoto H; Matsumoto Y; Nakashima Y; Oda Y
    Oncol Rep; 2021 Jan; 45(1):379-389. PubMed ID: 33155664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
    Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
    Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
    Zhang ML; Kem M; Mooradian MJ; Eliane JP; Huynh TG; Iafrate AJ; Gainor JF; Mino-Kenudson M
    Mod Pathol; 2019 Apr; 32(4):511-523. PubMed ID: 30367104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
    Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
    Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma.
    Okada M; Nakayama H; Okumura S; Daisaki H; Adachi S; Yoshimura M; Miyata Y
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1384-91. PubMed ID: 21440264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.
    Hattori A; Suzuki K; Matsunaga T; Fukui M; Tsushima Y; Takamochi K; Oh S
    Interact Cardiovasc Thorac Surg; 2014 Mar; 18(3):329-34. PubMed ID: 24351509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
    Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
    Front Immunol; 2020; 11():839. PubMed ID: 32536910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solitary ground-glass opacity nodules of stage IA pulmonary adenocarcinoma: combination of 18F-FDG PET/CT and high-resolution computed tomography features to predict invasive adenocarcinoma.
    Zhou J; Li Y; Zhang Y; Liu G; Tan H; Hu Y; Xiao J; Shi H
    Oncotarget; 2017 Apr; 8(14):23312-23321. PubMed ID: 28423576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1365-71. PubMed ID: 22883546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2012 Mar; 143(3):607-12. PubMed ID: 22104678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
    Mitchell KG; Parra ER; Nelson DB; Zhang J; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    J Thorac Cardiovasc Surg; 2019 Sep; 158(3):911-919.e6. PubMed ID: 31235357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression.
    Toyokawa G; Takada K; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Nov; 18(6):e375-e383. PubMed ID: 28385373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas.
    Okada M; Tauchi S; Iwanaga K; Mimura T; Kitamura Y; Watanabe H; Adachi S; Sakuma T; Ohbayashi C
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1448-54. PubMed ID: 17532938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.